Since central systolic pressure is considered an important surrogate parameter of afterload relating to future cardiovascular outcomes, these data suggested the beneficial roles of SGLT2 inhibitors in patients with T2DM [62,63]. Here, SLC5A2 is linked to type 2 diabetes mellitus.